Major Phase Applications Sample Clauses

Major Phase Applications. Major Phase Applications submitted to the Agency shall be in the form of six (6) hard copies and one (1) digital file. A Major Phase Application shall include the following documents:
View SourceView Similar (6)
Major Phase Applications. Specific details regarding the New TIHDI Units, such as the program, building configuration, unit types and sizes, the potential for including a mixture of New TIHDI Units and Authority Units in the same building, and specific developers and service providers for the New TIHDI Units, are not known at this time, nor is it anticipated that they will be known at the time the Amended and Restated TIHDI Agreement is finalized. As a result, the Amended and Restated TIHDI Agreement will outline a Major Phase planning process between the Authority and TIHDI that is coordinated with the Major Phase planning process, close of escrow, and horizontal development under the TICD DDA. At the time TICD submits each Major Phase application in accordance with the TICD DDA, the Authority and TIHDI will meet and confer to agree on the following: a) The exact locations and sizes of the Developable Pads for the New TIHDI Units in that phase. Criteria for the selection of TIHDI's Developable Pads will include (i) selection criteria used for applications for tax credits and other financing (which criteria may include proximity to certain services), (ii) proximity to other services that support the residents in supportive housing, and (iii) the preference for sites that can accommodate on-grade structured parking. b) The program for delivery of the New TIHDI Units based on (i) acknowledgement of the then current programs for the Existing TIHDI Units and TIHDI's preference to continue the programs and providers of the Existing TIHDI Units at the time, (ii) the Authority and City policy priorities regarding affordable, supportive housing and supportive homeless housing, (iii) available non-project generated capital funding sources, and (iv) operating issues including available operating subsidies, operating efficiencies associated with sizes of buildings, etc. The program for delivery of the 250 TIHDI Replacement Units will use the criteria described above as a starting point. The Amended and Restated TIHDI Agreement may include other mutually agreed upon criteria applicable to the 250 TIHDI Replacement Units. c) Whether any projects in that phase will include a mixture of New TIHDI Units and Authority Units. d) The schedule of delivery for the TIHDI Developable Pads, the vertical construction subsidy (including the moving cost payments) and other project- generated financing such as tax increment, housing impact fees, etc. for the New TIHDI Units to be constructed in such phase. e)...
View SourceView Similar (2)
Major Phase Applications. Authority Staff shall review each Complete Major Phase Application as expeditiously as reasonably possible. No later than fifteen (15) days after the expiration of the 30-day City Agency review period described in Section 4.2.2 above, Authority Staff shall provide Developer with a summary of all comments received from City Agencies, Authority Staff and any other comments by applicable City Agencies and other Governmental Entities and community organizations consulted by the Authority. Authority Staff shall provide final comments on each Complete Major Phase Application within eighty (80) days following the Authority’s determination that the Major Phase Application is a Complete Application. Authority Staff may propose changes to the Complete Major Phase Application that do not conflict with the Redevelopment Requirements, including changes responding to comments received by City Agencies or others during the 30-day City Agency review period. If Authority Staff proposes any such changes, then the Authority and Developer shall promptly meet and confer in good faith for a period of not more than forty-five (45) days, as such period may be extended by mutual agreement, to reach agreement on any such changes proposed by the Authority; provided such meet and confer period shall run concurrently with, and shall not extend, the eighty (80) day period specified above unless agreed to by Developer and Authority Staff. Upon the later of (i) the expiration of the eighty (80) day period specified above, as such eighty (80) day period may be extended by mutual agreement of Developer and Authority Staff, or (ii) the occurrence of the applicable Major Phase Decision Agreement, the Executive Director shall submit the Complete Major Phase Application to the Authority Board for review and consideration, with or without Authority Staff recommendation as applicable, at the next regularly-scheduled meeting for which an agenda has not yet been finalized and for which the Authority can prepare and submit a staff report in keeping with standard practices of the Authority. The Authority Board shall take action on each Complete Major Phase Application in accordance with the standards in Section 4.2.4 within thirty (30) days after such Complete Major Phase Application is introduced at a public meeting of the Authority Board for review and consideration, unless Developer in its sole discretion Approves an extension of such period. Failure of the Executive Director to submit the Comple...
View Source
Major Phase Applications. Before any tentative subdivision maps or vertical development projects may be approved for a particular Major Phase, the horizontal developer must submit a Major Phase Application for the reasonable approval by the Authority. The Major Phase Application will provide conceptual designs for site design, street layouts, public open space, infrastructure layout, sustainability measures, building footprints, and maximum building massing and heights, all as consistent with the Design for Development. The Major Phase Application must also catalogue all applicable CEQA mitigation measures and the process for implementation of such measures. The DRDAP will provide that the Authority will not disapprove a particular aspect of conceptual design if the Authority had previously approved such aspect in a pending or previous Major Phase if applicable.
View Source
Major Phase Applications 
View Source

Related to Major Phase Applications

  • Mobile Application If Red Hat offers products and services through applications available on your wireless or other mobile Device (such as a mobile phone) (the "Mobile Application Services"), these Mobile Application Services are governed by the applicable additional terms governing such Mobile Application Service. Red Hat does not charge for these Mobile Application Services unless otherwise provided in the applicable additional terms. However, your wireless carrier's standard messaging rates and other messaging, data and other rates and charges will apply to certain Mobile Application Services. You should check with your carrier to find out what plans your carrier offers and how much the plans cost. In addition, the use or availability of certain Mobile Application Services may be prohibited or restricted by your wireless carrier, and not all Mobile Application Services may work with all wireless carriers or Devices. Therefore, you should check with your wireless carrier to find out if the Mobile Application Services are available for your wireless Device, and what restrictions, if any, may be applicable to your use of such Mobile Application Services.

  • Background and Narrative of Budget Reductions 2. Assumptions Used in the Deficit Reduction Plan: - EBF and Estimated New Tier Funding: - Equal Assessed Valuation and Tax Rates: - Employee Salaries and Benefits: - Short and Long Term Borrowing: - Educational Impact: - Other Assumptions: - Has the district considered shared services or outsourcing (Ex: Transportation, Insurance) If yes please explain:

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • COVID-19 Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.